Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest growing pharmaceutical companies in Turkey across Human Pharma and Animal Health. Özlü highlights diabetes and specialty care as the main drivers of Boehringer Ingelheim’s success and explains their recent and upcoming investments in localization and clinical trials.
Agility is of paramount importance and the COVID-19 pandemic has engendered huge changes in market dynamics
